R&D Spending Showdown: PTC Therapeutics, Inc. vs Viridian Therapeutics, Inc.

Biotech R&D: PTC vs. Viridian's Decade of Growth

__timestampPTC Therapeutics, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 201479838000293000
Thursday, January 1, 20151218160001002000
Friday, January 1, 2016117633000888000
Sunday, January 1, 201711745600019623000
Monday, January 1, 201817198400030421000
Tuesday, January 1, 201925745200034794000
Wednesday, January 1, 202047764300028304000
Friday, January 1, 202154068400056886000
Saturday, January 1, 2022651496000100894000
Sunday, January 1, 2023666563000159765000
Loading chart...

Unlocking the unknown

The R&D Race: PTC Therapeutics vs. Viridian Therapeutics

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, PTC Therapeutics, Inc. has consistently outpaced Viridian Therapeutics, Inc. in R&D investment. From 2014 to 2023, PTC Therapeutics increased its R&D spending by over 730%, reaching a peak of approximately $667 million in 2023. In contrast, Viridian Therapeutics, while showing significant growth, expanded its R&D budget by a staggering 54,400%, from a modest $293,000 in 2014 to nearly $160 million in 2023. This dramatic increase highlights Viridian's aggressive push into the biotech arena. As these two companies continue to innovate, their R&D investments will likely play a pivotal role in shaping their future successes and the broader biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025